Dr. Michael R. Jordan is an attending physician in the Division of Infectious Diseases and Geographic Medicine at Tufts Medical Center and is an Assistant Professor of Medicine and Public Health and Community Medicine at Tufts University School of Medicine. Dr. Jordan is board certified in Infectious Diseases.
Dr. Jordan is a graduate of Tufts University School of Medicine and the Harvard School of Public Health. He has a broad interest in general infectious disease with special emphasis on HIV and emerging pathogens.
Dr. Jordan is an internationally recognized expert in HIV drug resistance (HIVDR), public health surveillance epidemiology, and antiretroviral therapy (ART) program evaluation and monitoring. His research interests include HIVDR, HIV subtypes, characterizing the clinical relevance of low-frequency HIVDR mutations, development of population level surveillance strategies for assessing levels of transmitted and acquired HIVDR in resource limited countries scaling-up ART, the development of strategies to optimize quality of ART service delivery in resource limited countries, and best practices and methods of assessing adherence in people taking pre-exposure prophylaxis for the prevention of HIV.
Dr. Jordan is the Director of Tufts Medical Center/Tufts University COVID-19 Biorepository and Comprehensive COVID-19 Database designed to accelerate research efforts in basic pathophysiology, diagnostics, vaccines, treatments, and clinical determinants and outcomes. His COVID-19 research includes the development of ultra-sensitive single genome sequencing assays to detect intra- and inter-host diversity of SARS-CoV-2, antiviral drug resistance, and immune escape. A pioneer in transdisciplinary research and its methods, he collaborates widely including with basic scientists at the Cummings School of Veterinary Medicine at Tufts University on the study of differences in COVID-19 outcomes due to sex and gender in both animal models and humans.
Dr. Jordan is Key Faculty at the Tufts Clinical and Translational Science (CTS ) Graduate Program and the Tufts Center for the Integrated Management of Antimicrobial Resistance (CIMAR) core faculty. Dr. Jordan is also key faculty for the Infectious Disuse fellowship training program and mentors residents and fellows in HIV-related research and diagnostics as well as surveillance epidemiology.
Dr. Jordan is an author of over 75 peer reviewed manuscripts, numerous WHO publications and scientific abstracts. He has recently been appointed to the Scientific Committee of the International Workshop on HIV Drug Resistance and Treatment Strategies and represents the Medical Center and University on the Massachusetts Consortium on Pathogen Readiness (MassCPR) Accelerator Committee.
Dr. Jordan is Co-Chair of the World Health Organization (WHO) HIVDR Surveillance and Monitoring Working Group and sits on the WHO HIV Drug Resistance Network (WHO/HIVResNet) Steering Committee.
Dr. Jordan supports WHO in the development and implementation of global HIVDR surveillance protocols. He is also a member of WHO’s Quality of HIV Care and Treatment Working Group and the WHO Advocacy group for HIVDR literacy and prevention. In addition, Dr. Jordan is a consultant scientist for the World Health Organization and Pan American Health Organization and has led global development of WHO/HIVResNet, a network comprised of more than 50 international institutions, experts, and national HIV program representatives, which builds capacity for HIVDR surveillance in low-and middle-income countries. Since 2005, Dr. Jordan has worked with Ministries of Health from over 60 countries to implement sustainable HIVDR surveillance and monitoring strategies and develop laboratory quality assurance/quality control and capacity for viral load and HIVDR testing.
- MPH, Harvard School of Public Health
- MD, Tufts University School of Medicine
- BA, Tufts University
- Infectious Disease Fellowship, Tufts Medical Center
- Internal Medicine Residency, Tufts Medical Center
HIV-1 subtypes, HIV drug resistance, Phylogenetic analysis, HIV drug resistance in resource-limited settings, COVID-19, emerging pathogens, surveillance epidemiology